 |
 |
 |
 |
 |
 |
 |
 |
Lamivudine (3TC, Epivir)
The Basics
- A Clinical Overview of Lamivudine (3TC, Epivir) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health - Prescribing Information for Lamivudine (3TC, Epivir) (PDF) (October 2006)
From GlaxoSmithKline - Drug Interactions: Lamivudine (August 2004)
From Project Inform
News
- Epivir Tablets for Pediatric Dosing (February 7, 2008)
From U.S. Food and Drug Administration - Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration - WHO Approves New Generic Lamivudine, Fluconazole Pills (July 14, 2004)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - WHO Removes Cipla's Lamivudine, Zidovudine Generics From Approved Drug List (June 16, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Drug Development News: Fixed-Dose Combinations (May/June 2004)
The Food and Drug Administration's fast-track approval process for fixed-dose combinations is about to bear fruit.
In GMHC Treatment Issues, from Gay Men's Health Crisis - FDA Bits: 3TC, Amprenavir and Nandrolone (September 2002)
Once-a-day dosing for 3TC (Epivir) approved; new interaction warnings for amprenavir (Agenerase); nandrolone decanoate returns to the U.S. market.
In HIV Treatment ALERTS!, from The Center for AIDS
Research
- Clinical Trials Using Lamivudine (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health - Literature Citations for Lamivudine (Regularly Updated)
From U.S. National Institutes of Health - A Clinical Overview of Zidovudine/Lamivudine (Combivir) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health - Dose-Ranging, Randomized, Clinical Trial of Atazanavir With Lamivudine and Stavudine in Antiretroviral-Naive Subjects: 48-Week Results
In AIDS - Prospective Randomized Trial of Emtricitabine Versus Lamivudine Short-Term Monotherapy in Human Immunodeficiency Virus-Infected Patients
In Journal of Infectious Diseases - Once-Daily Lamivudine + Nevirapine + Tenofovir Leads to High Failure Rates in Treatment-Naive Individuals (March 8, 2007)
In aidsmap.com - Emtricitabine and Lamivudine May Be Similar, but Their Resistance Profiles Differ in Important Ways (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections - HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO - Lamivudine Monotherapy Better Than Treatment Interruption in Rescue Patients With M184V (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - Adverse Event Risk on Abacavir + Lamivudine Is Not Higher for Patients Coinfected With Hepatitis B and/or Hepatitis C (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - Once-Daily Abacavir + Lamivudine + Tenofovir Fails in Naive Patients (April 2005)
In Expert Opinion on Investigational Drugs, from The Body PRO - Fixed-Dose Pill of Abacavir/Lamivudine Taken Once a Day Is Comparable to Twice-a-Day Abacavir + Lamivudine (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - No Difference Seen in Resistance Profiles of Emtricitabine and Lamivudine (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Sequencing and 2 of the Most Popular Backbone Regimens (February 25, 2005)
A comparison of resistance mutations with abacavir + lamivudine versus tenofovir + lamivudine.
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Failure of Tenofovir/Abacavir/Lamivudine Combination Still Unexplained (July 13, 2004)
In The XV International AIDS Conference, from The Body PRO - Lamivudine/Abacavir Is an Effective Nucleoside Backbone in Combinations Other Than With Tenofovir (July 13, 2004)
Results suggest that the K65R mutation is behind the failure of this three-drug combination.
In The XV International AIDS Conference, from The Body PRO - Virologic Failure Analyzed in a Trial of Once-Daily Versus Twice-Daily Abacavir/3TC Regimens (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - High Rate of Virologic Failure With Once-Daily ddI/3TC/TDF (November 2003)
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
To read PDF, click here
From U.S. Food and Drug Administration - Interim Analysis of Failure of Tenofovir/Abacavir/3TC Regimen (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - A Comparison of AZT/3TC vs. d4T/ddI, Plus Efavirenz, Nevirapine or Indinavir/Ritonavir (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Emergence of Resistance-Associated Mutations Over 96 Weeks in Patients Initiating ABC/3TC + d4T, EFV or APV/r (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - FTC Compares Well to 3TC in Triple-NRTI Regimens (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - FTC Similar in Most Ways to 3TC (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Viread, Epivir and Ziagen Combination -- Failure in Naive Patients With a Once-Daily Regimen (September/October 2003)
Daniel S. Berger, M.D., chief investigator in study ESS30009, examines what went wrong.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network - Early Virologic Non-Response in Patients With HIV Infection Treated With Lamivudine, Abacavir and Tenofovir (July 25, 2003)
"Dear Healthcare Provider" letter from GlaxoSmithKline.
From U.S. Food and Drug Administration - Abacavir/3TC/Tenofovir Combination Fails in Treatment-Naive Patients (July 14, 2003)
Analysis by Benjamin Young, M.D., Ph.D.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Abacavir/3TC/Tenofovir Combination Failure in Treatment-Naive Patients (July 14, 2003)
Analysis by Timothy Wilkin, M.D.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Separated at Birth: 3TC and FTC (July 2003)
A quick comparison of molecular structures.
In TAGline, from Treatment Action Group - Tenofovir Disoproxil Fumarate and Lamivudine Combination Therapy Compared to Lamivudine Alone for HBV in Therapy-Naive HIV/HBV Co-Infected Patients: 48-Week Interim Results (February 12, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Prospective Study of Regional Body Composition in Antiretroviral-Naive Subjects Randomized to Receive Zidovudine + Lamivudine or Didanosine + Stavudine Combined With Nelfinavir, Efavirenz or Both: A5005s, a Substudy of ACTG 384 (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Stavudine When Used in Combination With Lamivudine and Efavirenz in HIV-1 Infected Patients Naive to Antiretroviral Therapy: 48-Week Interim Results (July 12, 2002)
In The XIV International AIDS Conference, from The Body PRO - Anti-Hepatitis B Virus Activity of Tenofovir Disoproxil Fumarate in Lamivudine Experienced HIV/HBV Co-Infected Patients (July 10, 2002)
In The XIV International AIDS Conference, from The Body PRO - Abacavir/Lamivudine in Combination With Efavirenz, Amprenavir/Ritonavir or Stavudine: ESS40001 (CLASS) Preliminary 48-Week Results (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - Durability and Tolerability of the Triple NRTI Regimen Abacavir/Zidovudine/Lamivudine Based on Therapy Changes in Antiretroviral Therapy-Naive Patients in the Frankfurt HIV Cohort (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - High Incidence of Primary NNRTI Mutations and M184V in Isolates From Therapy-Experienced Adults Entering the ZORRO Trial (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - Zidovudine and Lamivudine Seminal Plasma: Blood Plasma Concentration Ratios Do Not Predict Total SP Exposure (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - Breastfeeding Wrecks Short Course Anti-HIV Treatment for Babies (April 10, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Studies Examine Switching Off d4T to Reverse Lipoatrophy (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Combivir/Abacavir/Nelfinavir, or Stavudine/Lamivudine/NFV (ESS40002) (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Comparative Results (Phase II 48-Week): BMS-232632, Stavudine, Lamivudine as HAART for Treatment-Naive HIV-Positive Patients (AI424-008) (December 17, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO - Lack of Clinically Relevant Drug-Drug Interactions Between Tenofovir DF and Efavirenz, Indinavir, Lamivudine and Lopinavir/Ritonavir in Healthy Subjects (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO - HBV: Lamivudine -- When to Start, When to Stop (October 23, 2001)
In 66th Annual Scientific Meeting of the American College of Gastroenterology, from The Body PRO - Prevalence and Predictive Value of Intermittent Viremia With Combination HIV Therapy (July 23, 2001)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - A Randomized Open Label Study to Investigate Abacavir and Lamivudine as Once-Daily Components of a Triple-Combination Regimen (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Abacavir, Lamivudine and Amprenavir +/- Ritonavir Is a Potent and Well-Tolerated HAART Regimen in Therapy-Naive Subjects (Preliminary Results from GW Protocols) (COL30325) (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Comparison of the Plasma Pharmacokinetics of Lamivudine During Twice-Daily and Once-Daily Dosing in HIV-1 Infected Individuals (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Efficacy and Safety of Switch to 3TC 300 mg QD vs. Continued 3TC 150 mg BID in Subjects with Virologic Suppression on Stable 3TC/d4T/PI Therapy (COLA4005): Final 24-Week Results (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Use of Trizivir to Simplify Therapy in HAART-Experienced Patients With Long-Term Suppression of HIV-RNA: TRIZAL Study (AZL30002) -- 24-Week Results (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Incidence of Resistance in a Double-Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir Plus Stavudine and Lamivudine
In Journal of Infectious Diseases - Change to Abacavir-Lamivudine-Tenofovir Combination Treatment in Patients With HIV-1 Who Had Complete Virological Suppression
In The Lancet
Clinical Management
Clinical Management
  |
  |